Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Study authors enrolled patients identified through the international prospective cohort International Ovarian Tumor Analysis Phase 5 (IOTA5) study who were older than 18 years with at least 1 ovarian tumor who had been selected for conservative management after an ultrasound assessment. Follow-up for patients was still ongoing at the time the study results were published.
In total, the study enrolled 1919 women from 10 different countries who had been diagnosed with noncancerous ovarian cysts. Researchers found that the cumulative incidence of spontaneous resolution of the cysts within 2 years of follow-up was 20.2% (95% CI, 18.4%-22.1%). Only 12 women were subsequently diagnosed with ovarian cancer, making the risk of malignancy 0.4% (95% CI, 0.1%-0.6%), although the authors cautioned that this could be due to a misdiagnosis of the tumors on the initial ultrasound scan. The rates of other complications, such as a torsion and a cyst rupturing, were 0.4% and 0.2%, respectively.
The study authors noted that these potential risks must be weighed against the risks of surgery, such as bowel perforation, which for women aged 50 to 74 years is between 3% to 5%.
Overall, the authors found that the “results suggest that the risk of malignancy and acute complications is low if [ovarian tumors] with benign ultrasound morphology are managed conservatively, which could be of value when counselling patients, and supports conservative management of [ovarian tumors] classified as benign by use of ultrasound.”
References
Froyman W, Landolfo C, deCock B, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicenter, prospective, cohort study [published February 5, 2019]. Lancet Oncol. doi: 10.1016/S1470-2045(18)30837-4.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More